Akorn (NASDAQ:AKRX) Analyst Rating Consensus

Akorn (NASDAQ:AKRX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.67 by 12 Brokerage Firm. 7 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 3 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Equity Analysts at the William Blair maintains the rating on Akorn (NASDAQ:AKRX). The brokerage firm has issued a Outperform rating on the shares. The Analysts at the ratings agency lowers the price target from $58 per share to $36 per share. The rating by the firm was issued on March 23, 2016.

Akorn (NASDAQ:AKRX) stock has received a short term price target of $ 36.4 from 10 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $4.95. The higher estimate of target price is $45 , while the lower price target estimate is $30

Akorn (NASDAQ:AKRX) witnessed a decline in the market cap on Tuesday as its shares dropped 0.9% or 0.26 points. After the session commenced at $29.16, the stock reached the higher end at $29.22 while it hit a low of $28. With the volume soaring to 1,233,071 shares, the last trade was called at $28.75. The company has a 52-week high of $48.5. The company has a market cap of $3,434 million and there are 119,427,471 shares in outstanding. The 52-week low of the share price is $17.57.

Akorn, Inc. has lost 4.83% in the last five trading days and dropped 5.89% in the last 4 weeks. Akorn, Inc. is up 9.23% in the last 3-month period. Year-to-Date the stock performance stands at -22.94%.

Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.